Related Experiment Video
Updated: Nov 2, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Considerations for use of direct oral anticoagulants in arterial disease
Deborah M Siegal1,2, Sonia S Anand3,4,5
1Department of Medicine University of Ottawa Ottawa ON Canada.
Insights
Direct oral anticoagulants (DOACs) show promise in managing cardiovascular diseases like stroke and peripheral arterial disease. This review examines DOACs alongside antiplatelet therapies for better patient outcomes.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Cardiovascular diseases caused 18 million deaths in 2017.
- Despite advances, patients face significant risks of recurrent cardiovascular events.
- Effective anticoagulation strategies are crucial for managing these conditions.
Purpose of the Study:
- To review randomized clinical trials on direct oral anticoagulants (DOACs).
- To evaluate DOACs in acute coronary syndromes, ischemic stroke, and peripheral arterial disease.
- To present considerations for combined DOAC and antiplatelet therapy.
Main Methods:
- Narrative review of randomized clinical trials.
- Focus on studies evaluating DOACs for specific cardiovascular conditions.
- Analysis of treatment strategies including single/dual antiplatelet therapy and low-dose DOACs.
Main Results:
- DOACs are evaluated for acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease.
- The review discusses the use of single antiplatelet therapy, dual antiplatelet therapy, or low-dose DOACs with antiplatelet therapy.
- Considerations for optimizing treatment regimens are presented.
Conclusions:
- DOACs represent an important therapeutic option in managing various cardiovascular conditions.
- Combining DOACs with antiplatelet therapy requires careful consideration of risks and benefits.
- Further research may refine optimal anticoagulation strategies for these patient populations.
Abstract:
Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low-dose DOACs used together with antiplatelet therapy are presented.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

